Phase I study of nilotinib in patients (pts) from Japan with imatinib-resistant Ph plus chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL)

被引：0

作者：

Tojyo, A.

Miyazaki, Y.

Usui, N.

Kobyashi, Y.

Okamoto, S.

Oyashiki, K.

Nishimura, M.

Okada, M.

Natori, H.

Tanii, H.

机构：

[1] Univ Tokyo, Tokyo, Japan

[2] Nagasaki Univ Hosp Med & Dent, Nagasaki, Japan

[3] Jikei Univ Hosp, Tokyo, Japan

[4] Natl Canc Ctr, Tokyo, Japan

[5] Keio Univ Hosp, Tokyo, Japan

[6] Tokyo Med Univ Hosp, Tokyo, Japan

[7] Chiba Univ Hosp, Chiba, Japan

[8] Hosp Hyogo Coll Med, Hyoko, Japan

[9] Novartis Pharmaceut, E Hanover, NJ USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

17511

引用

页数：2